THANK YOU FOR SUBSCRIBING
Halo Labs currently serves customers from the drug discovery phase through formulations and bioprocessing, empowering researchers to learn more about the stability and quality of their biological drugs faster and with more accuracy
Fremont, CA: Life science instrumentation company Halo Labs secured USD 12 million in a Series B1 round of funding led by Research Corporation Technologies. The company which develops tools for biologics researchers will use the additional funds for expanding Halo Labs' world-wide Sales presence and the continued development of the company's next-generation product portfolio. Halo Labs is also actively looking to acquire complementary technologies and companies to expand into the analytical particle space. The round was also participated by BroadOak Capital Partners, BioAdvance, top-level industry executive Paul McEwan, and other current employees.
"The success of Horizon, especially in the Gene Therapy field, provides confirmation that next-generation product development is critical. There is so much more this technology can provide in a variety of markets," said Robert Wicke, CEO of Halo Labs. "One of our latest customers, the US FDA, will be using the product to help understand the risks for patients on drug product manufacturing. This is a further indication that Horizon is the product of choice for particle analysis in the subvisible range.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The Horizon instrument performs high throughput subvisible particle (SVP) analysis using volumes as low as 25 µL. This ensures that the samples can be saved for other examinations or other replicates. The instrument has a 96 membrane plate, which allows several parameters to be tested in a short amount of time without dilution or sample preparation.
"Horizon is crucial at every stage of biologic drug formulation," said Chad Souvignier, Vice President of Research Corporation Technologies. "In early stages, it can reveal SVP formation missed by other techniques such as light obscuration and flow imaging. In later stages, it can differentiate proteins from extrinsic particles such as glass and plastic. And given the experience of the Halo Labs management team in product development and Sales, we are eager to find other technologies that we can help bring to market."
Halo Labs currently serves customers from the drug discovery phase through formulations and bioprocessing, empowering researchers to learn more about the stability and quality of their biological drugs faster and with more accuracy. Over the years, Halo Labs has received many prestigious awards and has received many research grants from agencies including DARPA, FDA, NSF, NIST, and NIH.
Check out: Top Drug Discovery and Development Solution Companies
More in News